Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia (Q73477695)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10688158%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10688158%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

1 reference

J Lavalaye

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10688158%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

D H Linszen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10688158%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

J Booij

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10688158%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

L Reneman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10688158%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

B P Gersons

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10688158%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

E A van Royen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10688158%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

language of work or name

English

0 references

publication date

1 November 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10688158%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10688158%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

92

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10688158%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10688158%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

33-44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10688158%20AND%20SRC:MED&resulttype=core&format=json

A rating scale for drug-induced akathisia

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Radioreceptor binding profile of the atypical antipsychotic olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: baseline rate in a group of patients from an Irish catchment area

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Effects of lorazepam administration on striatal dopamine D2 receptor binding characteristics in man--a positron emission tomography study

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

A new framework for investigating antipsychotic action in humans: lessons from PET imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Clozapine occupies high levels of dopamine D2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

In vivo 123 I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Dynamic SPECT in two healthy volunteers to determine the optimal time for in vivo D2 dopamine receptor imaging with123I-IBZM using the rotating gamma camera

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

In vitro and in vivo D2-dopamine receptor binding with [123I]S(-) iodobenzamide ([123I]IBZM) in rat and human brain

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging.

1 reference

https://api.crossref.org/works/10.1016%2FS0925-4927%2899%2900032-3

7 January 2021

10.1016/S0925-4927(99)00032-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10688158%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference